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Sodium salicylate (SS) is a widely used medication with side effects on hearing. In order to
understand these side effects, we recorded sound-driven local-field potentials in a neural
structure, the dorsal cortex of the inferior colliculus (ICd). Using a microiontophoretic tech-
nique, we applied SS at sites of recording and studied how auditory responses were
affected by the drug. Furthermore, we studied how the responses were affected by
combined local application of SS and an agonists/antagonist of the type-A or type-B γ-
aminobutyric acid receptor (GABAA or GABAB receptor). Results revealed that SS applied
alone enhanced auditory responses in the ICd, indicating that the drug had local targets in
the structure. Simultaneous application of the drug and a GABAergic receptor antagonist
synergistically enhanced amplitudes of responses.The synergistic interaction between SS
and a GABAA receptor antagonist had a relatively early start in reference to the onset of
acoustic stimulation and the duration of this interaction was independent of sound inten-
sity. The interaction between SS and a GABAB receptor antagonist had a relatively late
start, and the duration of this interaction was dependent on sound intensity. Simultane-
ous application of the drug and a GABAergic receptor agonist produced an effect different
from the sum of effects produced by the two drugs released individually.These differences
between simultaneous and individual drug applications suggest that SS modified GABAer-
gic inhibition in the ICd. Our results indicate that SS can affect sound-driven activity in the
ICd by modulating local GABAergic inhibition.
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INTRODUCTION
Sodium salicylate (SS) is a widely used medication with side effects
on hearing (1–5). The side effects include temporary hearing loss
and transient tinnitus (6–11). In animal models, SS can cause con-
ditioned behaviors as if experimental subjects perceived phantom
sounds (12–19).
The effect of SS on hearing is likely related to changes caused by
the drug in physiological processes in peripheral and central audi-
tory structures [see Ref. (5, 20–22) for reviews]. In the auditory
periphery, the drug can bind onto anion binding sites of the motor
protein prestin (23). Such binding suppresses the electromotility
of outer hair cells and reduces the output of the sensory organ
(24–26). In spite of this reduction in the output, amplitudes of
sound-driven local-field potentials (LFPs) in the central auditory
structure, the inferior colliculus (IC), are not changed following
systemic injection of SS (22, 27). The amplitudes of LFPs in the
auditory cortex (AC) and the medial geniculate nucleus are even
enhanced by the same drug manipulation (16, 22, 27, 28). These
Abbreviations: AC, auditory cortex; AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; Bac, baclofen; BF, best frequency; BMI, bicuculline methio-
dide; DN, negative deflection of a local-field potential; DP, positive deflection of a
local-field potential; GABA, γ-aminobutyric acid; IC, inferior colliculus; ICc, cen-
tral nucleus of the inferior colliculus; ICd, dorsal cortex of the inferior colliculus;
ICx, external cortex of the inferior colliculus; LFP, local-field potential; MT, mini-
mum threshold (i.e., the threshold at the best frequency); Musc, muscimol; NMDA,
N -methyl-d-aspartate; SS, sodium salicylate.
findings suggest that SS can directly change physiological processes
in the central auditory system, which compensates for the drug-
induced reduction in the output from the auditory periphery. In
addition to sound-driven responses, spontaneous firing of neurons
in structures such as the AC and the external cortex of the IC (ICx)
can also be enhanced by systemic injection of SS (29–31). These
results also suggest that the drug can directly affect physiological
processes in central auditory structures. Existing results indicate
that the effect of SS on auditory neural responses is predominantly
restricted to non-lemniscal parts of the auditory system (5, 21, 22).
In vitro neurophysiological/pharmacological methods have
been used to investigate mechanisms through which SS affects
neural activity. Experiments conducted in the AC, IC, hippocam-
pal cornu ammonis area 1 (i.e., CA1 area), and spinal dorsal horn
suggest that SS can affect inhibitory neurotransmission mediated
by γ-aminobutyric acid (GABA) (32–35).
As the IC is a structure essential for hearing, it is significant
to examine the effect of SS on auditory activities in the structure.
There is evidence showing that GABAergic inhibition plays a major
role in auditory responses in the IC (36–39) and SS can modulate
GABAergic neurotransmission in the structure (34). Therefore, it
is possible that the drug can change sound-driven responses in
the structure through modulating local GABAergic neurotrans-
mission. Area differences exist in the effect of SS on neural activity
in the IC. For instance, while systemic injection of the drug leads
to an enhancement in spontaneous activity in neurons in the ICx
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(29), it causes a reduction in spontaneous activity in neurons in a
specific area of the central nucleus of the IC (ICc) (40).
The effect of SS on neural activities in the dorsal cortex of
the IC (ICd) has not been evaluated so far. As a non-lemniscal
part of the auditory midbrain, this structure has high levels of
GABA (41–44) and GABAergic receptors (42, 45–50). Therefore,
the present study was designed to investigate the effect of local
SS on auditory responses in the ICd and to find whether such
an effect was related to a change in local GABAergic inhibition.
Sound-driven LFPs were recorded in the ICd. SS and a GABAergic
receptor agonist/antagonist were released individually as well as
simultaneously at sites of recording using a microiontophoretic
technique. Our results indicate that local SS can enhance audi-
tory responses in the ICd. Such enhancement is likely related to a
modulation of GABAergic inhibition.
MATERIALS AND METHODS
ANIMAL PREPARATION
Experiments were conducted using 26 male adult Wistar albino
rats (Rattus norvegicus) with body weights between 250 and 500 g.
The rats were obtained from Charles River Canada Inc., Saint
Constant, QC, Canada. Anesthesia was induced by combined
injections of ketamine hydrochloride (60 mg/kg, i.m.) and xylazine
hydrochloride (10 mg/kg, i.m.) and was maintained by supple-
mental injections of ketamine hydrochloride (20 mg/kg, i.m.) and
xylazine hydrochloride (3.3 mg/kg, i.m.). Recordings were per-
formed when a rat was inside a CL-15A LP single-wall sound-
attenuated booth (Eckel Industries, Morrisburg, ON, Canada).
The rat’s head was held firmly by a headbar attached to a Model 900
stereotaxic instrument (Kopf Instruments, Tujunga, CA, USA).
A small craniotomy was made for placing an electrode assembly
into the left ICd. Procedures were approved by the University of
Windsor Animal Care Committee and were in accordance with the
guidelines of the Canadian Council on Animal Care.
ACOUSTIC STIMULATION
Acoustic waveforms were generated digitally using a System 3 real-
time signal processing system controlled by a personal computer
running OpenEx software (Tucker-Davis Technologies, Alachua,
FL, USA). Sounds were delivered to the ear contralateral to the
recording site (i.e., the right ear) using a CF1 closed-field speaker
(Tucker-Davis Technologies, Alachua, FL, USA) connected to a
short piece of Tygon tubing inserted in the rat’s external mea-
tus. Brief monaural tone bursts with 2-ms rise/fall times (without
a plateau) were used to elicit auditory responses. The sound-
generating system was calibrated over a frequency range between
100 and 45,000 Hz using a 7017 condenser microphone (ACO
pacific, Belmont, CA, USA).
ELECTRODES FOR PHYSIOLOGICAL RECORDINGS AND
PHARMACOLOGICAL MANIPULATIONS
A piggy-back electrode assembly as described in a previous publi-
cation (51) was used in experiments. The single-barrel recording
electrode (impedance 300–500 kΩ) of the assembly was filled with
either 2 M NaCl or 3% N -(2-aminoethyl) biotinamide hydrochlo-
ride (Neurobiotin, Vector Laboratories SP-1120, Burlingame, CA,
USA) in 0.5 M sodium acetate.
Of the five barrels of the drug-releasing pipette, one was filled
with SS (50 mM, pH 3.5, Sigma-Aldrich S3007, Oakville, ON,
Canada). The second and third barrels were filled with bicu-
culline methiodide (BMI, 25 mM, pH 3.5, Sigma-Aldrich B6889,
Oakville, ON, Canada), an antagonist for the type-A GABAer-
gic receptor (GABAA receptor), and CGP35348 (25 mM, pH 3.5,
Sigma-Aldrich C5851, Oakville, ON, Canada), an antagonist for
the type-B GABAergic receptor (GABAB receptor). Alternatively,
the two barrels were filled with the GABAA receptor agonist musci-
mol (Musc, 10 mM, pH 3.5, Sigma-Aldrich M1523, Oakville, ON,
Canada) and the GABAB receptor agonist baclofen (Bac, 10 mM,
pH 3.5, Sigma-Aldrich B5399, Oakville, ON, Canada), respectively.
The remaining barrels were filled with 165 mM NaCl. The vehi-
cle of Bac was a citrate buffer, while that of the other drugs was
165 mM NaCl. Drugs were released iontophoretically using a Neu-
rophore BH-2 microiontophoresis system (Harvard Apparatus,
Saint Laurent, QC, USA).
EXPERIMENTAL PROCEDURES
An electrode assembly was driven into the left ICd from a dorso-
rostro-lateral to a ventro-caudo-medial location of the brain [see
Ref. (51, 52) for details] using a model 2660 micropositioner
(Kopf,Tujunga,CA,USA). A−20 nA retention current was applied
to each barrel with a pharmacological agent when the electrode
assembly was in the brain. Neural signals were amplified by a
2400 A preamplifier (Dagan, Minneapolis, MN, USA) and sam-
pled at 24.414 kHz using the System 3 real-time signal processing
system.
For each rat, sound-evoked LFPs were recorded at a single site.
Trains of contralaterally presented tone bursts were used to search
for a site where large LFPs could be elicited. Each train had 9 tone
bursts with their frequencies equally spaced on a logarithmic scale.
The 9 tone bursts were presented in a randomized order at a con-
stant rate of 4/s and a fixed level of 70 dB SPL. A sound-evoked LFP
had a relatively small positive deflection (DP) followed by a large
negative deflection (DN) (see Figure 1A, for example). The total
duration of the response was about 40 ms. Upon identification of
a recording site, trains of tone bursts with reduced sound-pressure
levels and frequency ranges were used to determine the best fre-
quency (BF) and the threshold at BF (i.e., the minimum threshold
or MT) at this site.
An LFP in response to a BF tone burst was recorded at the MT
and multiple sub- and supra-threshold sound-pressure levels. Peak
amplitude by sound-pressure-level functions and peak latency by
sound-pressure-level functions were created for the DP and DN of
an LFP. A tone burst was presented 300 times at each level for pro-
ducing an averaged evoked LFP. Tone burst presentations (Total
number: number of levels× 300) were produced in a randomized
order at a rate of 4/s.
An LFP was also recorded at multiple (typically 9) frequen-
cies at a fixed sound-pressure level at 10–30 dB above the MT.
These frequencies were evenly spaced on a logarithmic scale, with
the middle frequency equal to the BF and the range covering the
frequency response area of the recording site. Peak amplitude by
sound-frequency functions and peak latency by sound-frequency
functions were created for the DP and DN of an LFP. A tone
burst was presented 300 times at each frequency for generating
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FIGURE 1 | An example showing the effect of SS on an LFP recorded in
the ICd. (A) Left panel: LFPs evoked by a tone burst at the BF (2.7 kHz) and
10 dB above the MT of the recording site [as indicated by an arrow in the top
left panel of (B)] before, during, and after application of SS. (A) Right panel:
an LFP evoked by the same sound when a microiontophoretic current of
100 nA (the maximum current used in drug release in this case) was applied
to an electrode barrel containing saline vehicle alone. LFPs recorded before
application of SS and after recovery are also shown in the panel.
(B,C) Dependences of the peak amplitude (upper panels) and the peak
latency (bottom panels) of the DN (B) and the DP (C) on the sound-pressure
level (left panels) and sound frequency (right panels). In both (B,C), results
shown in the left panels were obtained at the BF of the recording site.
Results shown in the right panels were obtained at 20 dB above the MT of
the recording site.
an averaged evoked LFP. Tone burst presentations (Total number:
number of frequencies× 300) were produced in a randomized
order at a rate of 4/s.
Sodium salicylate and a receptor agonist (Musc or
Bac)/antagonist (BMI or CGP35348) were released individually
or in combination. Under each drug condition, dependences
of peak amplitudes and peak latencies of the DP and DN on
sound-pressure level and sound frequency were examined when
a drug-induced increase/reduction reached a saturated level with
no further changes over a period of at least 15 min. For each case,
SS was always the first drug released. After the effect of SS reached
a saturated level, a neurotransmitter receptor agonist or antago-
nist was released while the application of SS was maintained. After
the effect of combined drug application reached a saturated level,
the release of SS was terminated and the effect of the agonist or
antagonist was examined. The release of the agonist or antagonist
was then discontinued and recovery was observed while a holding
current was re-applied.
In 9 of the 26 rats, LFPs were also recorded when the largest
combined current used in drug releases was applied to a barrel con-
taining a vehicle alone. The purpose was to ensure that changes
in auditory responses during microiontophoresis of drugs were
indeed caused by drugs but not electrical currents. These record-
ings were conducted after effects of SS and agonists/antagonists
were examined and auditory responses fully returned to pre-drug
levels. Results from each of the nine cases indicated that microion-
tophoretic currents did not change the waveform of an LFP. The
right panel of Figure 1A shows an example of an LFP recorded
when a current was applied to an electrode barrel containing
vehicle alone.
In spite of the fact that our stereotaxic coordinates result in
consistent placement of an electrode in the ICd (51), the site of
recording in the ICd was verified in two randomly chosen rats in
the present study. Following physiological recordings, neurobiotin
was released using a microiontophoretic current (5µA, 7-s on/off
times, total duration 15–25 min) generated by a Midgard Precision
Current Source (Stoelting, Wood Dale, IL, USA). Twenty minutes
after the completion of drug release, the rat was given an overdose
of sodium pentobarbital (120 mg/kg, i.p.) and transcardially per-
fused with 4% paraformaldehyde. After the brain was extracted, it
was cryoprotected in 30% sucrose for overnight. It was then frozen
sectioned at 40µm in the frontal plane using a CM1050 S cryo-
stat (Leica Microsystems, Heidelberg, Germany). An immuno-
histological reaction was conducted by using streptavidin-Alexa
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Fluor 568 conjugate (Molecular Probes, Eugene, OR, USA) and
the labeling was examined using a CTR 6500 microscope (Leica
Microsystems).
DATA ANALYSIS
The effect of a drug/drugs was evaluated by comparing the peak
amplitude and latency of a deflection (DN or DP) obtained before
and during application of the drug/drugs. A difference waveform
between the LFPs recorded during and before drug application
was used to evaluate the time course of drug-inducted changes.
A change in the amplitude of LFP caused by simultaneous appli-
cation of SS and a receptor agonist/antagonist was compared with
the sum of the changes caused by the two drugs applied individu-
ally. A disparity between simultaneous and individual applications
in the total effect of the drugs was used to indicate an inter-
action between the two drugs during simultaneous application.
Such interaction would suggest that a modulation of GABAer-
gic pathways/neurotransmission by SS. A larger total effect during
simultaneous application would indicate a synergistic interaction
between two drugs (53).
Statistical analysis was conducted by using IBM SPSS Statis-
tics 22 and a custom-made script based on MatLab and Simulink
(R2008b).
RESULTS
The effect of SS on sound-driven LFPs was studied in all the 26
rats (named as cases elsewhere in the text) used in this study. In
a subgroup of nine cases, we examined effects of BMI applied
individually and in combination with SS. In a subgroup of eight
cases, we examined effects of CGP35348 applied individually and
in combination with SS. There were seven cases used in both
the groups. For each of the seven cases, effects of BMI (alone
and in combination with SS) were examined first. Effects of
CGP35348 (alone and in combination with SS) were examined
after an LFP completely recovered from effects of BMI and SS.
Effects of Musc and Bac (each applied individually and in combi-
nation with SS) were investigated in two separate subgroups with
six and seven cases, respectively. Effects of GABAergic receptor
agonists/antagonists (alone and in combination with SS) were not
tested in the remaining three cases.
EFFECTS OF SS ON LFPs IN THE ICd
Sodium salicylate increased the amplitude of an LFP over the dura-
tion of the DN in a current-dependent manner. For the example
shown in Figure 1, the peak amplitude was increased by about
50% when SS was released at 50 nA and was more than doubled at
100 nA (Figure 1A left panel). The increase in the peak amplitude
of DN was observed over a wide range of intensities and frequencies
(Figure 1B top panels). The peak latency of DN was not affected by
the drug (Figures 1A,B bottom panels). The DN typically restored
its pre-drug shape about 20 min after the cessation of drug release
(Figures 1A,B), indicating that the effect of SS was reversible.
The effect of SS on the peak amplitude of an LFP was examined
at 10, 20, and 30 dB above the MT in each of the 26 cases. Group
results indicated that the effect of SS was significant [Figure 2A;
two-way repeated-measures ANOVA, F (1,25)= 24.28, p< 0.001].
Post hoc analysis revealed that the increase caused by the drug
was significant at all intensities (Tukey pairwise comparisons with
Bonferroni correction, p< 0.001 at all intensities). No statistical
differences existed between the peak latencies of the DN recorded
before and during the drug (Figure 2B).
The waveform of DP including its peak amplitude and latency
was not affected by SS (see Figures 1A,C, for example). Thus, no
further analyses were conducted on this deflection.
We examined the time window over which SS significantly
increased the amplitude of an LFP (Figure 3). At each specific
stimulus level, two LFPs recorded before and during application
of SS were paired for each of the 26 cases. The resulting 26 pairs of
LFPs were used to generate two grand-mean waveforms (top pan-
els in Figures 3A–C). Each waveform (either a recorded trace or a
grand mean) had 6104 data points, as a recording was conducted
over a 250 ms period at a sampling rate of 24.414 kHz. A Wilcoxon
signed-rank test was conducted at each of these 6104 points using
26 pairs of amplitude values obtained before and during applica-
tion of SS. A resulting p-value was used to indicate the level of
significance of the change caused by SS at this sampling point. A
FIGURE 2 | Group results (n=26) showing effects of SS on the peak amplitude (A) and peak latency of the DN (B). For making (A,B), data from each
animal were collected at the BF and 10, 20, and 30 dB above the MT of a recording sites. Double stars indicate statistical significance at the level of p<0.001.
Error bars represent SE.
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FIGURE 3 | Group results (n=26) showing the time window over
which SS enhances the amplitude of an LFP recorded at the BF of
the recording site. (A–C) are based on LFPs recorded at 10, 20, and
30 dB above the MT of a recording site. In the upper panels of
(A–C), dotted and dashed lines represent grand-mean waveforms of
LFPs recorded before and during SS, respectively. A solid black line is the
difference between two grand-mean waveforms. A white line with a
black background is a p-value (Wilcoxon signed-rank test) by time
function comparing the difference between the amplitudes of the two
grand-mean waveforms.
p-value by time curve obtained at 10 dB above the MT indicated
that SS significantly increased the amplitude of an LFP (p< 0.05)
at all points over a time window between 13.8 and 48.1 ms after the
onset of a stimulus (bottom panel in Figure 3A). This time win-
dow was to some extent wider at higher stimulus levels (compare
Figures 3B,C bottom panels with the Figure 3A bottom panel).
INTERACTIONS BETWEEN SS AND GABAergic RECEPTOR
ANTAGONISTS IN SHAPING LFPs
In nine cases, sound-driven LFPs were recorded when SS was
released along with the GABAA receptor antagonist BMI. For
the example shown in Figure 4, the peak amplitude of the DN
at 20 dB above the MT was increased by SS (released at 100 nA)
and BMI (released at 20 nA) by about 140 and 120%, respectively
(Figure 4A). Simultaneous application of the two drugs resulted
in an increase in peak amplitude by more than 530% (Figure 4A),
which was much larger than the sum of the increases caused by
the two drugs individually (a total of 260%). This disparity sug-
gested that a synergistic interaction existed between SS and BMI
in regulating an LFP. Such an interaction was observed over a wide
range of intensities and frequencies (Figure 4B). Effects of SS and
BMI peaked at almost the same time (Figure 4A). Nevertheless,
the effect of SS lasted longer than that of BMI.
Group results from nine cases (Figure 5A) confirmed findings
from the example shown in Figure 4. As results under different
drug conditions (i.e., control, SS alone, SS+BMI, and BMI alone)
were obtained from the same nine animals over time, a two-way
repeated-measures ANOVA was used for analyzing these results.
An interaction between the two group factors SS and BMI was
examined. At 10 dB above the MT, SS, and BMI released indi-
vidually caused significant increases in the peak amplitude of the
DN [F (1,8)= 106.79, p< 0.001 for SS; F (1,8)= 23.14, p< 0.005 for
BMI]. The two drugs released simultaneously caused an increase
larger than the sum of the increases caused by the two drugs
applied individually [F (1,8)= 8.631, p< 0.05]. Results obtained
at other supra-threshold intensities were consistent with those
obtained at 10 dB above the MT. Neither individual nor combined
application of SS and BMI changed the peak latency of the DN
(Figure 5B).
We examined the time window over which SS and BMI had
a synergistic interaction in regulating LFPs. Two waveforms were
formed at each sound-pressure level (10, 20, or 30 dB above the
MT) for each case. One was a difference waveform between the
LFPs obtained before and during simultaneous application of SS
and BMI (reflecting a total increase caused by the drugs applied
simultaneously). The other one was the sum of the two differ-
ence waveforms resulting from individual applications of the drugs
(reflecting a total increase caused by the drugs applied individu-
ally). Pairs of these waveforms from nine individual cases were uti-
lized to generate two grand-mean waveforms (Figures 6A–C upper
panels). At each of the 6104 sampling points (250 ms recording
trace sampled at 24.414 kHz), we examined the disparity between
the total increase caused by SS and BMI applied simultaneously
and the total increases caused by the drugs applied individually
(Wilcoxon signed-rank test, data from nine cases). Such a dispar-
ity was used to reflect a synergistic interaction between SS and
BMI. At 10 dB above the MT, a disparity (p< 0.05) existed at all
sampling points within a time window between 13.8 and 26.1 ms
after the onset of a stimulus (Figure 6A). Similar time windows
of interaction were observed at 20 and 30 dB above the MT (13.1–
26.2 and 13.4–26.2 ms after the onset of a stimulus, respectively)
(Figures 6B,C).
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FIGURE 4 | An example showing the interaction between SS and BMI.
(A) Left panel: LFPs evoked by a tone burst at the BF (2.8 kHz) and 20 dB
above the MT of a recording site [as indicated by an arrow in the top left panel
of (B)] before drug, during individual and simultaneous applications of SS and
BMI, and after recovery. (A) Right panel: difference waveforms showing
changes caused by individual and simultaneous applications of SS and BMI.
Also, shown in this panel is a waveform resulting from summation of changes
caused by individual applications of SS and BMI. (B) Left panels: amplitude by
sound-pressure level (top) and amplitude by sound-frequency (bottom)
functions of the DN obtained before drug, during individual and simultaneous
applications of SS and BMI, and after recovery. (B) Right panels: changes in
the peak amplitude of the DN caused by individual and simultaneous
applications of SS and BMI at various sound-pressure levels (top) and sound
frequencies (bottom). Also, shown in each of the right panels in (B) is a curve
resulting from summation of changes caused by individual applications of SS
and BMI.
In eight cases, recordings were conducted when SS was released
along with the GABAB receptor antagonist CGP35348. While SS
produced a large increase in the amplitude of the DN, the increase
caused by CGP35348 was moderate (Figure 7). These effects of the
drugs were observed over a wide range of sound intensities and
frequencies. The two drugs applied simultaneously produced an
increase much larger than the sum of the increases caused by the
two drugs applied individually, suggesting that SS and CGP35348
enhanced an LFP synergistically.
Group results from eight cases (Figure 8A) confirmed find-
ings from the example shown in Figure 7. At 10 dB above the MT,
individual applications of SS and CGP35348 caused significant
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FIGURE 5 | Group results (n=9) obtained at 10dB above the MT
showing effects of individual applications of SS and BMI (two middle
bars) and a simultaneous application of the drugs (the right bar) on the
peak amplitude (A) and the peak latency (B) of the DN. The horizontal line
in (A) represents the mean peak amplitude of the DN obtained before drug
application. Double stars indicate statistical significance at the level of
p<0.005. A single star indicates statistical significance at the level of
p<0.05. Error bars represent SE.
FIGURE 6 | Group results (n=9) showing time windows over which a
synergistic interaction exists between SS and BMI in enhancing the
amplitude of an LFP recorded at the BF of a recording site. (A–C) are
based on results obtained at 10, 20, and 30 dB above the MT of a recording
site. In (A–C), a white line with a black background in the bottom panel is a
p-value by time function showing statistical significance of the difference
between the total changes caused by individual and simultaneous
applications of SS and BMI.
increases in the peak amplitude of the DN, while simultaneous
application of the drugs caused an increase much larger than
the sum of those caused by individual applications of the drugs
[two-way repeated-measures ANOVA,F (1,7)= 49.99,p< 0.001 for
SS; F (1,7)= 22.17, p< 0.005 for CGP35348; F (1,7)= 6.78, p< 0.05
for the interaction between drugs]. Results obtained at other
supra-threshold sound-pressure levels were consistent with those
obtained at 10 dB above the MT. Group results indicated that
SS and CGP35348 did not affect the peak latency of the DN
(Figure 8B).
Using results from the eight cases and the same method as used
for analyzing results presented in Figure 6, we evaluated the time
window over which SS and CGP35348 had a synergistic interaction
in regulating the amplitude of an LFP (Figure 9). At 10 dB above
the MT, an interaction was observed at each time point over a
time window between 20.0 and 27.6 ms after the onset of stim-
ulation (Wilcoxon signed-rank test, p< 0.05). This time window
of interaction was increased to 19.2–29.3 and 18.8–33.1 ms at 20
and 30 dB above the MT, respectively (Wilcoxon signed-rank test
at each data point, p< 0.05).
INTERACTIONS BETWEEN SS AND GABAergic RECEPTOR AGONISTS
IN SHAPING LFPs
Sodium salicylate was released in combination with the GABAA
receptor agonist Musc in six cases, as shown by an exam-
ple in Figure 10. Musc consistently suppressed the DN of an
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FIGURE 7 | An example showing the interaction between SS and
CGP35348. (A) Left panel: LFPs evoked by a tone burst at the BF (2.4 kHz)
and 20 dB above the MT of a recording site [as indicated by an arrow in the top
left panel of (B)] before drug, during individual and simultaneous applications
of SS and CGP35348, and after recovery. (A) Right panel: difference
waveforms showing changes caused by individual and simultaneous
applications of SS and CGP35348. Also, shown in this panel is a waveform
resulting from summation of changes caused by individual applications of SS
and CGP35348. (B) Left panels: amplitude by sound-pressure level (top) and
amplitude by sound-frequency (bottom) functions obtained before drug,
during individual and simultaneous applications of SS and CGP35348, and
after recovery. (B) Right panels: changes in the peak amplitude of an LFP
caused by individual and simultaneous applications of SS and CGP35348 at
various sound-pressure levels (top) and sound frequencies (bottom). Also,
shown in each of the right panels of (B) is a curve resulting from summation
of changes caused by individual applications of the drugs.
LFP while SS consistently enhanced it when the drugs were
released individually. During simultaneous application of the two
drugs, the waveform of the DN always fell between the wave-
forms obtained during individual applications of the drugs (e.g.,
Figure 10A left panel). The change caused by the drugs released
simultaneously was different from the sum of the changes caused
by the drugs released individually (Figure 10A right panel),
suggesting that the drugs interacted with each other in regu-
lating a response. SS-induced enhancement and Musc-induced
suppression were observed over a wide range of sound intensities;
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FIGURE 8 | Group results (n=8) obtained at 10dB above the MT
showing effects of individual applications of SS and CGP35348 (two
middle bars) and a simultaneous application of the drugs (right bar) on
the peak amplitude (A) and latency (B) of the DN. A horizontal line in
(A) represent the mean peak amplitude of the DN obtained before drug
application. Double stars indicate statistical significance at the level of
p<0.005. A single star indicates statistical significance at a level of
p<0.05. Error bars represent SE.
FIGURE 9 | Group results (n=8) showing the time window over which a
synergistic interaction exists between SS and CGP35348 in enhancing
the amplitude of an LFP recorded at the BF of a recording site. (A–C) are
results obtained at 10, 20, and 30 dB above the MT of a recording site,
respectively. In (A–C), a white line with a black background in the bottom
panel is a p-value by time function showing statistical significance of the
difference between the total changes caused by individual and simultaneous
applications of SS and CGP35348.
and a disparity in the total effect of SS and Musc between
simultaneous and individual drug applications existed over these
intensities (Figure 10B).
The GABAB receptor agonist Bac was released individually and
in combination with SS in seven cases, as shown by an example in
Figure 11. Bac consistently suppressed the DN with or without the
presence of SS. Difference waveforms indicated that the change
caused by SS and Bac applied simultaneously was different from
the sum of changes caused by the two drugs applied individually,
suggesting that the drugs interacted with each other in regulat-
ing an LFP (Figures 11A,B right panels). The interaction between
SS and Bac was observed over a wide range of frequencies and
intensities (Figure 11B).
Results from individual cases indicated that SS and a GABAer-
gic receptor agonist interacted with each other in regulating an
LFP in the ICd. Depending on the relative strengths of the cur-
rents for releasing the drugs, the resulting waveform of DN can
have a positive polarity or negative polarity or a change of polarity
over time. Owing to the sensitivity of the waveform to currents,
no statistical analysis was performed on the interaction between
SS and a receptor agonist.
DISCUSSION
An understanding of the effect of SS on hearing is dependent
on identification of target structures of the drug and evalua-
tion of drug-induced changes in neural activity in the structures.
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FIGURE 10 | An example showing the interaction between SS and Musc.
(A) Left panel: LFPs evoked by a tone burst at the BF (2.7 kHz) and 30 dB
above the MT of the recording site [as indicated by an arrow in the top left
panel of (B)] before drug, during individual and simultaneous applications of
SS and Musc, and after recovery. (A) Right panel: difference waveforms
showing changes caused by individual and simultaneous applications of SS
and Musc along with a waveform resulting from summation of changes
caused by individual applications of the drugs. (B) Left panels: amplitude by
sound-pressure level (top) and amplitude by sound-frequency (bottom)
functions obtained before drug, during individual and simultaneous
applications of SS and Musc, and after recovery. (B) Right panels: changes in
the peak amplitude of an LFP caused by individual and simultaneous
applications of SS and Musc at various sound-pressure levels (top) and
frequencies (bottom). Also, shown in each of the two panels is a curve
resulting from summation of changes caused by individual applications of
the drugs.
Furthermore, it is dependent on examination of the effect of
the drug on neural mechanisms (e.g., neurotransmission) in the
structures.
IDENTIFICATION OF ICd AS A TARGET STRUCTURE OF SS
Sodium salicylate reduces inputs to the central auditory system by
suppressing electromotility of outer hair cells (23–26). However,
systemic application of the drug does not change the amplitude of
a sound-driven LFP in the IC (22, 27). This contrast suggests that
the drug can directly target the IC and/or brainstem structure(s),
enhancing the gain (i.e., the input–output relation) of the pathway
from the cochlear nucleus to the IC (27). Such a change in neural
activity offsets the reduction in the input to the central auditory
system.
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FIGURE 11 | An example showing the interaction between SS and Bac.
(A) Left panel: LFPs evoked by a tone burst at the BF (19.0 kHz) and 20 dB
above the MT of the recording site [as indicated by an arrow in the top left
panel of (B)] before drug, during individual and simultaneous applications of
SS and Bac, and after recovery. (A) Right panel: difference waveforms
showing changes caused by individual and simultaneous applications of SS
and Bac. Also, shown in this panel is a waveform resulting from summation
of changes caused by individual applications of SS and Bac. (B) Left panels:
amplitude by sound-pressure level (top) and amplitude by sound-frequency
(bottom) functions obtained before drug, during individual and simultaneous
applications of SS and Bac, and after recovery. (B) Right panels: changes in
the peak amplitude of an LFP caused by individual and simultaneous
applications of SS and Bac at various sound-pressure levels (top) and
frequencies (bottom). Also, shown in each of the two panels is a curve
resulting from summation of changes caused by individual applications of
SS and Bac.
Using in vitro physiological recordings/pharmacological
manipulations, people have identified the ICc and ICx as target
structures of SS (34, 54). The same approach has also been used
to find target structures of SS in the auditory forebrain (33, 55–
57). In the in vitro studies, circuits associated with a neuron under
investigation were only partially retained and inputs to the neuron
were artificially activated. Therefore, it is difficult to use results
from these studies to predict how local SS affects spontaneous and
sound-driven activities of neurons in a live animal. An in vivo neu-
rophysiological/pharmacological approach has been used to deal
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with this limitation. Using the in vivo approach, people have found
that local SS in the AC can reduce spontaneous activity but enhance
sound-driven activity in the structure (58). No results have been
published about how local SS affects sound-driven activities in
midbrain/brainstem structures.
In the present study, we recorded sound-evoked LFPs in the ICd
while applying SS microiontophoretically at recording sites. Our
results indicate that local SS can enhance auditory responses in
the ICd. As SS is a small molecule that can cross blood–brain bar-
rier, it is reasonable to believe that SS applied systemically can also
reach the ICd and lead to an enhancement in auditory activity in
the structure. As brain tissue is a volume conductor, an enhanced
auditory response in the ICd caused by local SS can lead to an
enhanced ensemble sound-driven response of the entire IC [e.g.,
an LFP recorded by Sun et al. (27)]. Such an enhancement can lead
to an increase in the gain of the IC. It has yet to be determined
whether local SS in the ICc and ICx can enhance auditory activi-
ties in the two subdivisions. Such enhancements could also lead to
increases in the gain of the entire IC. A sound-driven LFP in the IC
as an entity remains unchanged following systemic application of
SS (27). Thus, an increase in the gain of the IC caused by local SS
following systemic application of the drug should be accompanied
by a reduction in the input to the structure. Further experiments
are needed for evaluating the effect of SS on inputs to the IC.
An enhancement of auditory responses in the ICd by SS may
cause secondary changes in the ICc and ICx through intrinsic
projections (59–61). As excitatory/inhibitory natures of these pro-
jections are poorly understood, it is difficult to postulate whether
auditory activities in the ICc and ICx are enhanced or suppressed.
Elucidating secondary effects of SS can help fully understand the
effect of the drug on the auditory midbrain.
A direct effect of SS on sound-driven LFPs in the ICd does
not preclude the possibility that SS applied systemically can also
enhance neural activity in the ICd through affecting sources of
inputs to this structure. The ICd receives major inputs bilaterally
from the AC (59, 62–67). Descending projections from the AC
are likely excitatory in nature (68). An enhancement of auditory
activity following systemic injection of SS has been observed in
the AC (27, 28, 30, 58, 69, 70). This enhancement can very likely
be reflected in sound-driven responses in the ICd. SS may also
affect auditory activity in the ICd through affecting activity in the
ICc and ICx, which provide intrinsic projections to the ICd (59–
61). Knowledge about effects of SS on auditory responses in the
ICc and ICx and information about excitatory/inhibitory natures
of the intrinsic projections are needed for evaluating the depen-
dence of auditory activity in the ICd on the ICc and ICx following
systemic application of SS.
Technical limitations need to be taken into consideration in
the interpretation of results from the present study. An LFP is a
weighted average of potential changes generated by current dipoles
at the vicinity of a recording electrode (71–73). Current dipoles
located as far as a few hundred micrometers away from an electrode
can contribute to an LFP (74, 75). Owing to the close proxim-
ity of the ICd to an area in the ICc where neurons with low
characteristic frequencies congregate, an LFP evoked by a low-
frequency sound recorded in the ICd may include contributions
from these low-frequency ICc neurons. As neurons in the ICx are
not tonotopically organized, a single tone burst unlikely activates
many ICx neurons bordering the ICd. Therefore, contribution of
the ICx to an LFP recorded in the ICd is likely limited. It is decent
to believe that LFPs recorded in the present study were predom-
inantly dependent on the ICd, in spite of possible contributions
from the ICc (51).
SS AND GABAergic NEUROTRANSMISSION IN THE ICd
Our results reveal that simultaneous application of SS and a
GABAergic receptor agonist or antagonist produces a change
in the amplitude of an LFP different from the total change
caused by the two drugs applied individually. These results sug-
gest that SS can either directly or indirectly modulate GABAergic
neurotransmission in the ICd.
Brain slice studies have revealed that SS can reduce the release of
GABA in IC neurons. This reduction is at least partly due to sup-
pression of serotonergic inputs to the GABAergic neurons (34).
Such reduction can lead to disinhibition of neurons innervated by
GABAergic projections. An SS-induced reduction in the release of
GABA has also been observed in the AC. In this structure, SS can
reduce activity of fast spiking interneurons (presumable inhibitory
neurons releasing GABA) and suppress inhibitory postsynaptic
currents in pyramidal neurons in layers II/III (neurons receiving
GABAergic inputs) (33, 56).
Results from the present study suggest that SS can modulate
GABAergic receptors. It is certain that sound-driven LFPs are dif-
ferent from postsynaptic potentials recorded from neurons in a
brain slice preparations. However, it is believed that postsynaptic
currents are among the most important current dipoles for gen-
erating an LFP (71–73, 76–78). Thus, a comparison of the time
course of activation of a GABAergic receptor with the time win-
dow over which a synergistic interaction exists between SS and an
antagonist of the receptor can provide useful information about
the subtypes of receptors modulated by SS.
The interaction between BMI and SS was found between about
13.5 and 26 ms after the onset of a sound and was not dependent
on the sound-pressure level. This time window is in general agree-
ment with the time course of an inhibitory postsynaptic potential
mediated by the GABAA receptor, which peaks at about 5 ms after
activation of GABAergic inputs and has a halfwidth of about
23 ms (79).
The time window over which SS had a synergistic interaction
with CGP35348 was from about 20 ms to about 27.6 ms after
the onset of a sound at 10 dB above the MT and was wider at
high-sound-pressure levels. This fact suggests that postsynaptic
GABAB receptors are unlikely major targets of SS. Activation of
such receptors by a single brief synaptic input can result in an
inhibitory postsynaptic potential lasting for over 800 ms (80).
Repetitive acoustic stimulation at a rate of 4/s (as used in the
present study) would lead to sustained inhibition due to extensive
temporal integration among individual postsynaptic potentials.
Thus, application of SS and CGP35348 would have resulted in dis-
inhibition over a much longer time window. Presynaptic GABAB
receptors regulating the release of GABA are also unlikely major
targets of SS. Suppression of these receptors by SS and CGP35348
would lead to a net inhibitory effect on postsynaptic neurons and
a reduction in auditory activity.
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It is speculated that presynaptic GABAB receptors regulating
the release of glutamate may have been affected by SS. Neuro-
transmitter receptors activated by glutamate include the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor
and the N -methyl-d-aspartate (NMDA) receptor. A postsynap-
tic potential mediated by the AMPA receptor peaks at about
5 ms after the activation of a glutamatergic input and has a
halfwidth <15 ms, while a potential mediated by the NMDA
receptor peaks at about 25 ms and has a larger halfwidth (79).
The amplitude and duration of a potential mediated by the
NMDA receptor are increased by depolarization of the cell mem-
brane. Thus, similarities exist in the time course and level depen-
dence between SS-CGP35348 synergistic interaction and NMDA
receptor-mediated postsynaptic potentials. Such similarities sug-
gest that the enhancement in sound-driven LFP during simultane-
ous application of SS and CGP35348 could be due to an increase
in glutamate release and consequent enhancement in postsynap-
tic potentials mediated by NMDA receptors. This postulation
needs to be tested by future neurophysiological/pharmacological
experiments.
Our results do not rule out the possibility that the effect of SS on
LFPs in the ICd may also be related to direct modulation of other
neurotransmitter receptors and ion channels. In vitro studies in the
IC indicate that SS can suppress glycine receptors withα1-subunits
(81). In spiral ganglion neurons, aspirin can augment responses
mediated by NMDA receptors (82). In the IC and AC, SS blocks
voltage-gated sodium channels and L-type calcium channels (55,
83, 84). At high doses, SS or aspirin can inhibit acid-sensing ion
channels (85). All these receptors and ion channels are possible
targets of SS in the ICd.
EFFECTS OF SS: BEYOND GABAergic NEUROTRANSMISSION IN THE ICd
Our results from the ICd strongly suggest that SS can enhance
auditory responses through modulating local GABAergic recep-
tors. It is likely that such modulation and a resulting enhancement
in auditory response can occur beyond the ICd following systemic
drug application, as GABAergic receptors also exist in other audi-
tory structures (45–49). Enhancements of sound-driven LFPs have
been found in the medial geniculate nucleus and the AC following
systemic application of SS (22). Such enhancements are likely at
least in part due to local modulation of GABAergic receptors.
Disinhibition in multiple structures in the auditory system may
result in alterations in physiological characteristics of neural cir-
cuits. It is important to find whether reverberation of circuit
and enhancement in synchronization among different auditory
structures occur as a result of systemic SS application. A study
of these alterations can help understand neurobiological bases of
SS-induced hearing problems.
It has yet to be determined whether and how modification of
GABAergic neurotransmission is responsible for SS-induced tin-
nitus. The relatively short-onset time of transient tinnitus (10)
seems supporting that such a hearing disorder is related to direct
modification of neural mechanisms. It is possible that SS-induced
reduction in GABAergic inhibition not only enhances sound-
driven responses (as revealed by our results) but also enables a
neuron to fire action potentials in the event of receiving spon-
taneously generated synaptic inputs not associated with external
acoustic stimuli. Such action potential firing may contribute to
tinnitus.
As revealed by manganese-enhanced functional magnetic res-
onance imaging, expression of immediate early gene c-fos, and
uptake of [14C] 2-deoxyglucose, chronic application of SS can
induce tinnitus-like behavior along with a widespread increase
in neural activity in the central auditory system (86–90). Struc-
tures showing a large increase in activity include the ICd. These
changes caused by chronic application of SS may be in part
due to direct modulation of GABAergic neurotransmission. They
may also be due to alterations of other neural mechanisms, such
as increase/reduction of the rate of receptor turnover and/or
up/down regulation of the expression of receptor proteins. These
homeostatic changes can cause side effects on hearing while help-
ing reestablish the balance between excitation and inhibition
tipped by SS.
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